FDA sees no heart risks from Novartis' Parkinson's drug

October 26, 2015 4:56 PM

21 0

FDA sees no heart risks from Novartis' Parkinson's drug

U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG's treatment, Stalevo, for Parkinson’s disease.

Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required clinical trial and one additional study. (1.usa.gov/1R9cqP6)

Read more

To category page

Loading...